| Identification | Back Directory | [Name]
MLi-2 | [CAS]
1627091-47-7 | [Synonyms]
MLi-2
rel-3-[6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-4-pyrimidyl]-5-[(1-methylcyclopropyl)oxy]-1H-indazole
1H-Indazole, 3-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-4-pyrimidinyl]-5-[(1-methylcyclopropyl)oxy]-, rel- | [Molecular Formula]
C21H25N5O2 | [MDL Number]
MFCD30536362 | [MOL File]
1627091-47-7.mol | [Molecular Weight]
379.46 |
| Chemical Properties | Back Directory | [Boiling point ]
625.8±55.0 °C(Predicted) | [density ]
1.257±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 15 mg/ml | [form ]
A crystalline solid | [pka]
11.24±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
MLi-2 is a leucine-rich repeat kinase 2 (LRRK2) inhibitor and may be used in the treatment and prevention of Parkinson’s disease as its a precursor to the illness. | [Definition]
ChEBI: MLI-2 is a member of the class of indazoles that is 1H-indazole that is substituted at position 3 by a 6-(cis-2,6-dimethylmorpholin-4-yl)pyrimidin-4-yl group and at position 5 by a (1-methylcyclopropoxy)group. It is an inhibitor of leucine-rich repeat kinase 2 (LRRK2). It has a role as an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor. It is a member of indazoles, a member of pyrimidines, a member of morpholines, a member of cyclopropanes, an aromatic ether and a tertiary amino compound. | [Biological Activity]
MLi-2 is an orally availableCNS activehighly potent and selective leucine-rich repe at kinase 2 (LRRK2) inhibitor. MLi-2 potently inhibits central and peripheral LRRK2 in mice. | [storage]
Store at -20°C |
|
|